That Collectively, this body of evidence suggests

The gap

Evidence profile

Sourced from the future work of the source papers, classified as general, spanning 3 journals.

Supporting evidence — 3 representative gaps

• Advances in the Application of Exosomes in the Treatment of Gynecological Malignant Tumors (2026) · International Journal of Biology and Life Sciences · doi

  immune evasion, In summary, exosomes, as multifunctional intercellular communication carriers, play a pivotal regulatory role in the initiation and progression of gynecological malignancies. They promote tumor advancement by reshaping the tumor microenvironment, mediating and regulating drug resistance, while also serving as therapeutic targets and drug delivery vehicles, offering novel therapeutic avenues for gynecological cancers. Current studies on cervical, ovarian, and endometrial cancers have demonstrated that strategies such as inhibiting tumor cell exosome secretion, blocking exosome-mediated signaling, and developing exosome-targeted drug delivery systems can effectively suppress reverse tumor proliferation and metastasis, chemotherapy resistance, and enhance antitumor immune responses, showing promising clinical application potential. However, research and application of exosomes in the gynecological malignancy treatment remain in varying isolation exploratory phase, with numerous critical issues requiring isolation and purification resolution. First, exosome techniques require optimization. Existing methods like ultracentrifugation and density gradient centrifugation struggle to achieve both high purity and high recovery rates and simultaneously. Furthermore, identification standards among research teams, coupled with the absence of standardized operational protocols, severely limit the reproducibility of research findings and the comparability of multi-center data. Second, the efficiency and specificity of exosome targeted delivery require improvement. Natural exosomes exhibit weaknesses such as poor targeting and susceptibility to clearance by the reticuloendothelial system. How to achieve precise recognition and enrichment of gynecological malignant tumor tissues through surface modification techniques while minimizing toxic side effects on normal tissues remains a key focus and challenge in current translational research. Third, the safety and long-term lack efficacy of exosome-based research sufficient therapeutic strategies support. Existing clinical data 109 Tian W, Chen K,Deng L, et al. Cancer associated fibroblast exosomal miR-214-3p regulated by hnRNPA2B1 promotes cisplatin resistance by inhibiting ferroptosis.[J].International journal of surgery (London, England),2025. Irani G M, Babaei S,Kazemi T. Exosomes in hepatocellular in tumor carcinoma: evasion, metastasis, immune microenvironment angiogenesis, and drug resistance.[J].Cell cycle (Georgetown, Tex.), 2025,1-23. reprogramming involvement the for Xu Z, Fang X,Wang S, et al. Tongue squamous cell carcinomaderived exosomes miR-21-5p affect tumor progression via promoting M2 macrophage polarization[J].

  generalfuture workevidence 5/5
  Keywords: tumor exosome exosomes gynecological drug resistance immune therapeutic delivery cell evasion progression microenvironment cancers current
• Engineered exosomes for targeted glioma therapy: overcoming the blood-brain barrier with nature-inspired nanocarriers (2026) · Discover Nano · doi

  Exosomes have demonstrated significant potential as drug delivery vehicles for glioma therapy, particularly because of their native biocompatibility, relatively low immuno- genicity, and emerging evidence for brain delivery capabilities [160]. In addition, their membrane and cargo can be engineered to enhance loading capacity, circulation sta- bility, and targeting performance. Despite this promise, translation remains limited by incomplete understanding of exosome biology, heterogeneous subpopulations, and practical barriers related to scalable production, consistent characterization, and pre- dictable in vivo behavior [161]. A key priority for future work is the development of rational and testable engineer- ing strategies that directly address BBB and blood brain tumor barrier constraints. Surface functionalization should be optimized to improve brain entry and glioma speci- ficity, including receptor mediated transcytosis targeting for BBB transport combined with tumor selective ligands for glioma homing. Dual targeting designs may reduce off target uptake while increasing intratumoral exposure. In addition, stimulus responsive approaches could improve local release and functional delivery, for example via pH sen- sitive or enzyme responsive mechanisms that exploit the acidic and protease rich glioma microenvironment. These designs should be evaluated with quantitative readouts that connect formulation parameters to BBB penetration, intratumoral drug levels, and bio- logical response [162]. Another major direction is improving cargo loading efficiency and selecting func- tionally relevant payloads. Current loading methods often remain inefficient for clini- cal translation, particularly for large hydrophilic agents and nucleic acid cargos, and basic incubation provides limited and variable encapsulation [161, 163]. Future plat- forms should prioritize scalable loading approaches that preserve vesicle integrity while enabling higher payloads and controlled release kinetics. Beyond single agent delivery, Rahmani et al. Discover Nano (2026) 21:87 Page 27 of 35 combination cargo concepts are likely to be increasingly important in glioma. Examples include co delivery of a cytotoxic drug with resistance modulators that address DNA repair related therapy failure, as well as payloads that reprogram immunosuppression within the tumor microenvironment [164]. From a translational perspective, standardization and manufacturing readiness are essential. Progress toward clinical adoption requires GMP compatible, scalable pro- duction workflows, such as controlled bioreactor based systems, alongside harmonized characterization panels that assess purity, identity, potency, stability, and batch to batch consistency [165]. Establishing robust potency assays that reflect intended mechanisms of action is critical because performance cannot be inferred from size and marker pro- filing alone. In parallel, rigorous safety and biodistribution evaluation should be priori- tized, including immunogenicity, off target organ accumulation, procoagulant potential, and long-term toxicity, especially under repeated dosing paradigms. Finally, more predictive preclinical validation is needed to reduce the gap between early proof of concept and clinical outcomes. This includes orthotopic glioma models and patient derived systems combined with quantitative imaging and pharmacokinetic profiling to evaluate delivery efficiency and therapeutic benefit. Exosomes also remain promising as biomarkers for diagnosis and monitoring, and future research should inte- grate standardized isolation and analysis pipelines to strengthen clinical interpretability [166, 167]. Overall, continued advances in exosome bioengineering, together with dis- ciplined translational development and standardized outcome measures, may substan- tially expand the role of engineered exosomes in precision glioma therapy [168–170].

  generalfuture workevidence 5/5
  Keywords: glioma delivery loading exosomes drug therapy brain cargo targeting scalable future tumor payloads clinical potential
• Direct neuronal reprogramming for neurological diseases: applications, translational Challenges, and future directions (2026) · Frontiers in Neuroscience · doi

  that Collectively, this body of evidence suggests the efficiency and specificity of AAV-mediated in vivo glial-to- neuron conversion, at least for NeuroD1 and PTBP1-based approaches, may be substantially lower than initially reported. However, it is essential to recognize that these controversies pertain specifically to in vivo AAV-mediated paradigms and do not invalidate the well-controlled in vitro reprogramming evidence using these same factors, where environmental variables are tightly regulated and lineage contamination is not a concern. The in vitro foundation remains robust and continues to offer valuable insights into the molecular mechanisms governing cell fate conversion. The challenge, therefore, lies in developing strategies that can faithfully translate these in vitro capabilities into the in vivo setting. Promising alternatives, such as hydrogel-mediated sustained delivery, astrocyte-targeted nanoparticle formulations, and non-viral delivery systems, are being explored to overcome the limitations of direct intracranial AAV injection (McCaughey- Chapman et al., 2024; McDowall et al., 2024). Furthermore, even if complete glial-to-neuron conversion proves difficult to achieve in vivo, partial reprogramming intermediates which often lead to cell death may be therapeutically exploitable, particularly in the context of glioblastoma therapy where inducing tumor cell death is the desired outcome.

  generalfuture workevidence 5/5
  Keywords: vivo mediated conversion vitro cell evidence speci glial neuron reprogramming delivery death collectively body suggests

Questions about this gap